JAK2V⁶¹⁷F/TET2 mutations: does the order matter?
作者信息
Pronier Elodie, Quivoron Cyril, Bernard Olivier A, Villeval Jean-Luc
出版信息
Haematologica. 2011 May;96(5):638-40. doi: 10.3324/haematol.2011.042846.
Abstract
摘要
相似文献
1
JAK2V⁶¹⁷F/TET2 mutations: does the order matter?JAK2V⁶¹⁷F/TET2 突变：顺序重要吗？
Haematologica. 2011 May;96(5):638-40. doi: 10.3324/haematol.2011.042846.
2
Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.TET2 突变在 JAK2V⁶¹⁷F 真性红细胞增多症中对造血系统影响的程度。
Haematologica. 2011 May;96(5):775-8. doi: 10.3324/haematol.2010.029678. Epub 2011 Jan 27.
3
DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.继发性急性髓系白血病长期缓解后真性红细胞增多症中的DNMT3A、TET2和JAK2突变
Leuk Lymphoma. 2016 Aug;57(8):1969-73. doi: 10.3109/10428194.2015.1122785. Epub 2015 Dec 24.
4
Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.真性红细胞增多症中造血克隆优势、干细胞突变及JAK2V617F等位基因负荷的进化模式
Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.
5
[Clinical features and gene mutation status of polycythemia vera and essential thrombocythemia in Japan].[日本真性红细胞增多症和原发性血小板增多症的临床特征及基因突变状态]
Rinsho Ketsueki. 2010 Jul;51(7):508-14.
6
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.真性红细胞增多症、原发性血小板增多症和骨髓纤维化中的TET2突变及其临床相关性
Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.
7
Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis.JAK2基因第12外显子的体细胞突变作为红细胞增多症的分子基础。
Haematologica. 2007 Dec;92(12):1585-9. doi: 10.3324/haematol.11506.
8
Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.红系祖细胞的克隆分析表明，聚乙二醇化干扰素α-2a治疗靶向JAK2V617F克隆，而不影响TET2突变细胞。
Leukemia. 2010 Aug;24(8):1519-23. doi: 10.1038/leu.2010.120. Epub 2010 Jun 3.
9
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.伴有JAK2外显子12和JAK2-V617F突变的真性红细胞增多症患者的克隆异质性
Blood. 2008 Apr 1;111(7):3863-6. doi: 10.1182/blood-2007-09-111971. Epub 2008 Jan 14.
10
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.JAK2 617V>F突变引发真性红细胞增多症患者原代细胞中的促红细胞生成素超敏反应和终末红系扩增。
Blood. 2007 Aug 1;110(3):1013-21. doi: 10.1182/blood-2006-10-054940. Epub 2007 Mar 27.
引用本文的文献
1
Inferring the temporal order of cancer gene mutations in individual tumor samples.推断个体肿瘤样本中癌症基因突变的时间顺序。
PLoS One. 2014 Feb 27;9(2):e89244. doi: 10.1371/journal.pone.0089244. eCollection 2014.
2
Myeloid malignancies: mutations, models and management.髓系恶性肿瘤：突变、模型与管理。
BMC Cancer. 2012 Jul 23;12:304. doi: 10.1186/1471-2407-12-304.
本文引用的文献
1
5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming.哺乳动物受精卵中的 5-羟甲基胞嘧啶与表观遗传重编程有关。
Nat Commun. 2011;2:241. doi: 10.1038/ncomms1240.
2
Advances in DNA methylation: 5-hydroxymethylcytosine revisited.DNA 甲基化的研究进展：再次探讨 5-羟甲基胞嘧啶。
Clin Chim Acta. 2011 May 12;412(11-12):831-6. doi: 10.1016/j.cca.2011.02.013. Epub 2011 Feb 12.
3
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells.Tet1 和 Tet2 调节小鼠胚胎干细胞中 5-羟甲基胞嘧啶的产生和细胞谱系特化。
Cell Stem Cell. 2011 Feb 4;8(2):200-13. doi: 10.1016/j.stem.2011.01.008.
4
Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.TET2 突变在 JAK2V⁶¹⁷F 真性红细胞增多症中对造血系统影响的程度。
Haematologica. 2011 May;96(5):775-8. doi: 10.3324/haematol.2010.029678. Epub 2011 Jan 27.
5
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.骨髓增殖性肿瘤：分子病理生理学、必要的临床理解和治疗策略。
J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711. Epub 2011 Jan 10.
6
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine.选择性化学标记揭示了 5-羟甲基胞嘧啶在全基因组范围内的分布。
Nat Biotechnol. 2011 Jan;29(1):68-72. doi: 10.1038/nbt.1732. Epub 2010 Dec 12.
7
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.白血病 IDH1 和 IDH2 突变导致超甲基化表型，破坏 TET2 功能，并损害造血分化。
Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9.
8
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.骨髓癌中突变型 TET2 导致 5-甲基胞嘧啶羟化作用受损。
Nature. 2010 Dec 9;468(7325):839-43. doi: 10.1038/nature09586.
9
JAK2 impairs stem cell function?JAK2是否会损害干细胞功能？
Blood. 2010 Sep 2;116(9):1392-3. doi: 10.1182/blood-2010-06-287318.
10
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.Tet 蛋白在 5mC 向 5hmC 的转化、胚胎干细胞自我更新和内细胞团特化中的作用。
Nature. 2010 Aug 26;466(7310):1129-33. doi: 10.1038/nature09303.
Zotero 插件